News
CRON
2.410
-0.41%
-0.010
'Senator Presses Attorney General Garland On Marijuana Banking Bill's Impact On Criminal Investigations' - Marijuana Moment
Democratic senator presses attorney general about a bipartisan marijuana banking bill. Sen. Jack Reed asked Merrick Garland for his opinion on a controversial section of the bill. Section 10 of the original bill would have required banks to notify criminals when their accounts are terminated. Garland says he can't comment on the specific provisions of the legislation.
Benzinga · 1d ago
'Marijuana Companies Ask Federal Court To Set Oral Arguments On DOJ Claim That Cannabis 'Tourism' Justifies Prohibition Enforcement' - Marijuana Moment
Marijuana companies are asking a federal court to schedule oral arguments in a case against the federal government. The Justice Department says cannabis legalization attracts out-of-state tourism and justifies prohibition. The companies are seeking to shield their in-state activities from federal enforcement. DOJ has filed a motion to dismiss the suit.
Benzinga · 3d ago
Canopy Growth to expedite entry into U.S. cannabis market
Canopy Growth to expedite entry into U.S. Cannabis market. Special meeting of shareholders approved creation of a new class of exchangeable shares. The cannabis firm is expected to accelerate entry into the US$50 billion in 2026 market. Shares of Canopy Growth were down over 1% premarket.
Seeking Alpha · 3d ago
Weekly Report: what happened at CRON last week (0408-0412)?
Weekly Report · 3d ago
7 Penny Stocks That Could Deliver 1,000% Returns by 2029
NASDAQ · 6d ago
FDA chief sees no reason for delay in cannabis rescheduling
FDA chief sees no reason for delay in cannabis rescheduling. The DEA is reviewing whether to reschedule marijuana from a high-risk to a low-risk category. A favorable decision will see marijuana move to a Schedule III drug category from its current Schedule I status.
Seeking Alpha · 04/11 19:38
'FDA Head Says There's 'No Reason For DEA To Delay' Rescheduling Marijuana' - Marijuana Moment
Benzinga · 04/11 18:14
Why Cronos Group Shares Are Falling
Cronos Group Inc (NASDAQ:CRON) shares are trading lower by 2.78% to $2.63 during Tuesday's session. Shares of cannabis stocks are trading in sympathy with Tilray, which fell after reporting worse-than-expected third-quarter results. Cronos Group does not pay a dividend but does have a buyback program.
Benzinga · 04/09 16:34
ACOR, HUBC and DATS among pre-market losers
On the Move ACOR, HUBC and DATS among pre-market losers. Vincerx Pharma presents positive preliminary phase 1 data for VIP236 and updates on pipeline progress. Neogen Corp. (NEOG) reports positive Q3 earnings release.
Seeking Alpha · 04/09 12:26
Tilray guidance cut sends cannabis stocks lower
Top cannabis player Tilray Brands revised down its full-year outlook with its Q3 financials on Tuesday. The company reported $188M in net revenue for the quarter, falling short of Wall Street forecasts. Tilray's peers Canopy Growth, Cronos and Aurora Cannabis are also trading lower in premarket trading.
Seeking Alpha · 04/09 11:42
NASDAQ-Listed Marijuana Stocks, Tilray, Canopy, Aurora Rally: What's Behind The Surge?
Senior analyst Pablo Zuanic says the Canadian cannabis sector is witnessing a notable upswing. Recent legislative changes in Canada, Germany and the U.S. Have positively impacted Canadian Licensed Producers. Most successful companies in the sector are valued at 2 to 3 times their sales. The most liquid Canadian LPs are Tilray, Aurora and Canopy Growth.
Benzinga · 04/08 22:33
Cronos Group Is Maintained at Underperform by B of A Securities
Dow Jones · 04/08 09:58
Cronos Group Price Target Raised to $2.50/Share From $2.00 by B of A Securities
Dow Jones · 04/08 09:58
B of A Securities Maintains Underperform on Cronos Group, Raises Price Target to $2.5
Benzinga · 04/08 09:48
Weekly Report: what happened at CRON last week (0401-0405)?
Weekly Report · 04/08 09:31
Cautious Outlook on Cronos Group Amid Slow Regulatory Progress in Cannabis Industry
Bank of America Securities analyst Lisa Lewandowski reiterated a Sell rating on Cronos Group (CRON – Research Report) on April 5 and set a price target of $2.50. Lewandowski’s rating is based on a cautious approach to the recent optimism surrounding regulatory changes in the cannabis industry.
TipRanks · 04/08 00:07
Tilray Could Break Down
Tilray's stock has bounced back by 55% since mid-November but is down 11% since September. The company's recent acquisitions have impacted its balance sheet. Analyst projections for Tilray's future revenue and adjusted EBITDA have weakened. The stock's chart remains challenging. Tilray Brands reports its fiscal Q3 on Tuesday.
Seeking Alpha · 04/07 13:47
Cannabis rally sparks concerns amid moves to mainstream
Pot stocks have bounced back from recent lows as investors await favorable regulatory changes in the U.S. And global developments. The Florida Supreme Court ruled in favor of legalizing recreational marijuana in the state this week. A potential rescheduling decision from the DEA could be "imminent"
Seeking Alpha · 04/06 17:29
Cannabis Stock Movers For April 4, 2024
Choom Holdings (OTC:CHOOF) shares closed up 39900.00% at $0.0004. Target Group shares also closed up 11.21%. CNBX Pharmaceuticals shares closed down 25.68% in the last day. Cronos Group and Canopy Gwth closed down.
Benzinga · 04/04 20:30
Trulieve-led Florida adult-use cannabis campaign gathers steam
More donors join Florida's adult-use cannabis legalization campaign. The initiative has been mainly funded by the state's leading cannabis retailer, Trulieve. Florida's Supreme Court greenlighted the initiative to go before voters in November. If passed, possession of up to three ounces of cannabis will be legal for adults in the state.
Seeking Alpha · 04/04 16:14
More
Webull provides a variety of real-time CRON stock news. You can receive the latest news about Cronos Group through multiple platforms. This information may help you make smarter investment decisions.
About CRON
Cronos Group Inc. is a Canada-based global cannabinoid company engaged in building intellectual property by advancing cannabis research, technology and product development. The Company’s segments include United States and Rest of World. The United States operating segment consists of the manufacture and distribution of hemp-derived CBD infused products. The Rest of World operating segment is involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. The Company’s international brand portfolio includes Spinach, PEACE NATURALS, and Lord Jones. The Lord Jones are hemp-derived cannabidiol (CBD) brand. Its Lord Jones Hash Fusions is a line-up of premium ice water hash infused pre-rolls. Its PEACE NATURALS offers Peppermint CBD, a blend of CBD extract, quality medium-chain triglycerides (MCT) oil, and a hint of natural peppermint flavor.